Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA's starting lineup

Parsing the first set of diseases in FDA's patient-focused initiative

Some of the 16 diseases FDA picked for its first round of public meetings under its Patient-Focused Drug Development initiative are obvious choices where it is not hard to imagine why the agency would need patient feedback. Others are genuine head-scratchers, and at least one surprised its own patient advocates with its inclusion.

FDA declined to discuss its rationale for the specific diseases it chose for the first round of meetings, which will be held over fiscal 2013-15. A second round of four disease-focused meetings is planned for FY16-FY17, bringing the total to 20, and the agency has said it has additional ways of addressing patient concerns in diseases not picked for the meetings.

The first meeting was held last month and focused on chronic fatigue syndrome (CFS) (see Cover Story).

The agency started with a list of 39 proposed diseases. According to a notice published in the Federal Register in April, FDA's criteria for picking the first 16 diseases included the severity and chronic nature of a condition, a lack of approved therapies, uncertainty about clinical endpoints, the total size of the patient population

Read the full 1824 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers